CORTICORELIN OVINE TRIFLUTATE
Acthrel (corticorelin ovine triflutate) is a protein pharmaceutical. Corticorelin ovine triflutate was first approved as Acthrel on 1996-05-23.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Corticorelin ovine triflutate
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Acthrel | corticorelin ovine triflutate | Ferring Pharmaceuticals | N-20162 DISCN | 1996-05-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acthrel | Biologic Licensing Application | 2021-11-12 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
corticorelin ovine triflutate, Acthrel, Ferring Pharmaceuticals Inc. | |||
| 2103-05-23 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0795 | Injection, corticorelin ovine triflutate, 1 microgram |
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep deprivation | D012892 | — | F51.12 | 2 | — | — | — | — | 2 |
| Pituitary neoplasms | D010911 | — | — | 1 | — | — | — | 1 | 2 |
| Pituitary diseases | D010900 | — | E23.7 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 1 | 1 |
| Acth-secreting pituitary adenoma | D049913 | — | — | — | — | — | — | 1 | 1 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | — | 1 | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CORTICORELIN OVINE TRIFLUTATE |
| INN | — |
| Description | Acthrel (corticorelin ovine triflutate) is a protein pharmaceutical. Corticorelin ovine triflutate was first approved as Acthrel on 1996-05-23. |
| Classification | Protein |
| Drug class | prehormones or hormone-release stimulating peptides; vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201591 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09067 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 37 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use